Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-744-6792
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$8.42 billion
Profitability
Miscellaneous
Employees21,100
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Bausch Health Companies (TSE:BHC) Frequently Asked Questions
What is Bausch Health Companies' stock symbol?
Bausch Health Companies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BHC."
How were Bausch Health Companies' earnings last quarter?
Bausch Health Companies Inc (TSE:BHC) issued its quarterly earnings data on Tuesday, August, 6th. The company reported $1.38 EPS for the quarter, missing the consensus estimate of $1.42 by $0.04. The firm had revenue of $2.88 billion for the quarter, compared to analysts' expectations of $2.89 billion. View Bausch Health Companies' Earnings History.
When is Bausch Health Companies' next earnings date?
What price target have analysts set for BHC?
0 Wall Street analysts have issued 12-month price objectives for Bausch Health Companies' stock. Their forecasts range from C$25.00 to C$28.00. On average, they expect Bausch Health Companies' stock price to reach C$26.50 in the next twelve months. This suggests that the stock has a possible downside of 13.4%. View Analyst Price Targets for Bausch Health Companies.
Has Bausch Health Companies been receiving favorable news coverage?
News articles about BHC stock have trended negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bausch Health Companies earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Bausch Health Companies.
Who are some of Bausch Health Companies' key competitors?
Some companies that are related to Bausch Health Companies include Canopy Growth (WEED), Merck KGaA (MRK), Aurora Cannabis (ACB), Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Hexo (HEXO), Knight Therapeutics (GUD), HEXO (HEXO), Green Organic Dutchman (TGOD), OrganiGram (OGI), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), Flowr (FLWR) and CannTrust (TRST).
What other stocks do shareholders of Bausch Health Companies own?
Who are Bausch Health Companies' key executives?
Bausch Health Companies' management team includes the folowing people:
- Mr. Joseph C. Papa, CEO & Chairman (Age 64)
- Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
- Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 54)
- Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
- Mr. Joseph Gordon, Pres & Co-Head Bausch + Lomb/International (Age 55)
How do I buy shares of Bausch Health Companies?
Shares of BHC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Bausch Health Companies' stock price today?
One share of BHC stock can currently be purchased for approximately C$30.59.
How big of a company is Bausch Health Companies?
What is Bausch Health Companies' official website?
How can I contact Bausch Health Companies?
The company can be reached via phone at 514-744-6792.
MarketBeat Community Rating for Bausch Health Companies (TSE BHC)
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
